本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
BANGKOK , THAILAND - Media OutReach Newswire - 16 January 2026 - The National Innovation Agency (Public Organization), or NIA, under the Ministry of Higher Education, Science, Research and Innovation (MHESI), is encouraging Thai entrepreneurs to keep a close eye on three key innovation trends for 2026: technology trends, market trends, and consumer trends. NIA also unveiled four major innovation policy directions: promoting investment in innovative businesses, strengthening innovation linkages across sectors, advancing regional innovation development, and enhancing national innovation competencies. These policies aim to accelerate the growth, capability development, and diffusion of innovative businesses, positioning them as key drivers of Thailand's sustainable economic and social development. Dr. Krithpaka Boonfueng, Executive Director of NIA Dr. Krithpaka Boonfueng, Executive Director of NIA, said that rapid advances in artificial intelligence, escalating geopolitical tensions across multiple regions, trade decoupling and reciprocal tariff measures that create uncertainty in the global economy and value chains, as well as environmental issues and natural disasters, were major forces shaping change in 2025. 'Innovation' remains a critical tool for coping with these disruptions and uncertainties. Looking ahead to 2026, Thai entrepreneurs will need to continue closely monitoring and adapting to change. Key innovation trends present both opportunities and challenges, starting with technology trends that help reduce costs and build long-term competitiveness. Notable technologies include Agentic AI, which can autonomously perform tasks such as customer chat responses, sales closure, order management, queue booking, price comparison, and automated purchasing; Hyper-Automation, which integrates bots and systems to reduce repetitive tasks, improve efficiency and accuracy, and enable real-time data-driven decision-making; and Carbon Accounting, which is becoming essential for SMEs involved in exports or global supply chains. Businesses are increasingly required to measure carbon footprints across energy use, production, logistics, and waste, in response to stricter global regulations such as the EU's CBAM and Thailand's forthcoming Climate Change Act. Business trends highlight growth opportunities across several sectors. These include Health and Wellness, covering not only treatment but also prevention and therapy, particularly for working-age populations facing stress, office syndrome, and sleep disorders. Opportunities span physical therapy clinics, aromatherapy and sleep-aid products, herbal supplements, wellness tourism, yoga, and meditation. Another fast-growing area is the Pet Economy, as the Thai pet market continues to expand despite economic headwinds. This sector now includes holistic and organic pet food, fresh pet meals, fashion apparel, multifunctional pet furniture, and premium services such as pet spas, hotels, and condominiums. Additionally, Green and Circular Businesses are gaining traction, with upcycling and recycling ventures transforming waste and local materials into higher-value products. Although costs may be higher, sustainability-driven products can command premium prices, creating opportunities for community-based SMEs through innovative design aligned with environmental and fashion trends. Consumer trends reveal a shift toward value-for-money and self-care. Hyper-Personalization is increasingly important, as consumers seek products tailored to individual needs, supported by advanced data analytics—such as supplements based on blood test results or skincare customized to personal skin conditions. Silver Solutions address the needs of Thailand's aging society, with services focused on convenience, safety, and quality of life, including home modifications, slow-life travel programs, and assisted healthcare services. Meanwhile, Muketing or the Magic Economy reflects the enduring role of belief, spirituality, and cultural traditions in Thai society, creating economic value through religious tourism, spiritually inspired products, and design-driven items that blend art with faith. Dr. Krithpaka added that NIA's long-term mission is to transform Thailand into an innovation-driven economy, with startups and innovation-based entrepreneurs at its core. This requires the creation of new industries to drive growth and position Thailand as an "Innovation Nation" through three key objectives: developing innovations based on advanced and deep technologies that are difficult to replicate; creating high-value products and services rooted in creativity and cultural capital; and preparing a highly skilled workforce capable of keeping pace with rapid technological change and evolving demographic and labor market structures. NIA works closely with domestic and international partners in its role as a Focal Conductor of Innovation, supporting innovative businesses through the 4G framework: Groom (incubation and capability building), Grant (funding support), Growth (market expansion and access to capital), and Global (international market entry). In 2026, NIA will drive Thailand's economy and society through four key innovation policy pillars. The first focuses on promoting investment in innovative businesses, offering a range of financial mechanisms including grants for early-stage ventures and co-investment schemes for growth-stage firms, such as corporate co-funding, public venture mechanisms (NIA Venture), global investment link programs, and capital gains tax exemptions to support startup fundraising. The second pillar emphasizes innovation linkages, strengthening collaboration between academia and industry to translate research into real-world applications through acceleration programs, innovation hubs, ecosystem platforms, tax incentives, and future mechanisms such as intellectual property financing. The third pillar supports regional innovation development, enhancing local economies and quality of life through Social Innovation Driving units (SID), Open Innovation programs, City and Community Challenge, Social Innovation Villages, and Ninmungkornth The Reality, which inspires new or small entrepreneurs to become local economic champions. The final pillar aims to enhance national innovation competencies, cultivating innovation mindsets, technological and business skills, entrepreneurial thinking, and global readiness across youth, startups, SMEs, and organizations. Key initiatives include STEAM4INNOVATOR, Startup Thailand League, NIA Academy training programs, and productivity-focused projects such as INNOProductivity for SMEs, aligned with international innovation management standards like ISO 56001. Through these integrated efforts, NIA seeks to strengthen Thailand's innovation ecosystem and ensure that innovative businesses can grow resiliently and compete on the global stage. Hashtag: #NIA #NationalInnovationAgencyhttps://www.nia.or.th/The issuer is solely responsible for the content of this announcement.
SINGAPORE, Jan. 16, 2026 /PRNewswire/ -- Panduit, a global leader in electrical and network infrastructure solutions, announced the promotion of Holly Garcia to Chief Commercial Officer on 13 January 2026. In this role, Garcia will lead the company's global commercial strategy, focusing on the company's commitment to innovation and delivering a best-in-class experience for customers. Garcia will report directly to Panduit President, Marc Naese. "Holly has the vision and expertise to position our company for continued growth and success while deepening our customer relationships," said Naese. "Holly's leadership as Chief Commercial Officer will be instrumental in strengthening the customer experience and delivering the value our markets expect." In her most recent role as Vice President of Panduit's Data Center business unit, Garcia spearheaded global growth and innovation initiatives. She led the development of business strategy and directed new product introductions to strengthen Panduit's position in the rapidly evolving data center market. With more than 25 years of experience in sales, marketing, and business unit leadership, Garcia brings a proven track record of driving commercial success and transformative growth. "I'm honored to take on the role of Chief Commercial Officer and excited to lead our commercial strategy during this time of growth," explained Garcia. "Our team's commitment to innovation and customer success has positioned us as a trusted partner globally, and I look forward to driving even greater value for our customers and stakeholders." About Panduit Panduit is a leading global manufacturer of high-quality electrical and network infrastructure and connectivity solutions. Operating from our headquarters in Tinley Park, Ill., USA, and across 112 worldwide locations, we drive innovation through strategic R&D investments and breakthrough product development while providing seamless global support and service. Since 1955, our commitment to our customers and partners has remained constant. And together, with them, we create exceptional solutions that support their businesses in a way that's good for them and good for the world. Panduit is making the connections that matter. For more information, visit www.panduit.com.
HSINCHU, Jan. 16, 2026 /PRNewswire/ -- YTTEK, a leading provider of wireless communication solutions, has been awarded a crucial contract by the Taiwan Space Agency (TASA) to develop the core communications payload for Taiwan's ambitious Beyond 5G (B5G) Low Earth Orbit (LEO) satellite initiative. Since the contract award in June 2025, the project has progressed steadily and has now entered the engineering verification phase. The contract, officially titled "Pathfinder Communication Payload Baseband Module Prototype Development," positions YTTEK at the forefront of the nation's push for space communication autonomy. YTTEK will leverage its core expertise in Software-Defined Radio (SDR) technology to design, implement, and verify the fundamental components of the first domestically developed LEO satellite payload. SDR at the core: Building the next-generation communications payloadTASA's B5G satellite initiative includes two experimental LEO spacecraft. The first payload (1A) was contracted to U.S.-based CesiumAstro, while the 1B satellite—designed to showcase Taiwan's indigenous aerospace capabilities—will be developed domestically. TASA will lead the 1B payload development in collaboration with top Taiwanese companies, including YTTEK, and research institutions. "We are honored to join TASA's national space team," said Jiangson Chen, CEO of YTTEK. "YTTEK will apply its deep experience in SDR system design to deliver a high-integration, high-value wireless communications payload that advances Taiwan's autonomy in LEO satellite technology." Strengthening Taiwan's space manufacturing and B5G competitivenessThe B5G experimental satellite program serves two missions: Technology validation and building Taiwan's domestic space supply chain. The Taiwan-developed 1B satellite is scheduled to launch in 2030. YTTEK's participation highlights the country's commitment to establishing a resilient and fully local communications payload ecosystem. As the Pathfinder phase of the 1B communications payload program formally enters the engineering verification stage, YTTEK's participation underscores Taiwan's commitment to building a resilient, fully indigenous communications payload ecosystem and strengthening its competitiveness in the global B5G landscape. Proven reliability: Validated by TASA missionsYTTEK specializes in SDR-based wireless communication-modules for satellites and defense-grade Unmanned Aerial Vehicles (UAVs). The company's HyperSDR satellite ground station modem has already demonstrated space-grade reliability by successfully receiving and decoding signals from TASA's Formosat-5 and NASA's Landsat-8 and Landsat-9 satellites. Building on these proven capabilities, YTTEK's participation in the Pathfinder payload program further extends its experience from ground-based systems to spaceborne communications payloads. About YTTEK TechnologyYTTEK, a leader in Software-Defined Radio (SDR), delivers cutting-edge wireless communication solutions for satellite communications, defense UAV and academia applications. We are dedicated to offering proven, reliable, and integrated communication solutions, helping customers accelerate product development and ensure exceptional performance. For more information, please visit https://yttek.com/solutions/satcom/.
Kuala Lumpur– AIMS is pleased to announce an official partnership with the Lamborghini Brand and its winery. This collaboration represents not only a powerful alliance between two leading brands from distinct fields, but also a dedicated effort to transcend traditional industry boundaries, creating an unprecedented platform of excellence for traders and brand enthusiasts across the Asia-Pacific region and globally. Lamborghini is not only an icon of ultimate automotive craftsmanship but has also extended its pursuit of luxury and quality into the world of wine. The spirit of resilience, excellence, and breakthrough embodied by its founder, Mr. Ferruccio Lamborghini, has been ingrained in the winery since its establishment in 1968. Faithfully continue Lamborghini's relentless pursuit of perfection and channeling the fighting spirit symbolized by the iconic Taurus emblem. "We are truly honored to enter into this partnership," mentioned by Aaron Chang, CEO of AIMS. "This goes far beyond a commercial linkage; it is a profound alignment of brand philosophies. AIMS is committed to providing users with exceptional and efficient service experience, empowering them to continually push boundaries and pursue the 'extraordinary' in their trading journey. This resonates perfectly with the Lamborghini founder's ethos of constantly challenging limits and pursuing perfection. We look forward to working together to open new doors for our clients, leading them toward greater achievements and unique experiences." "This partnership sets a new benchmark where elite trading services converge with legendary Italian luxury," said Mr. Stanley Ng, Principal Consultant & Advisor for the Lamborghini Brand and Winery in Southeast Asia. "We are confident that AIMS distinguished market presence and influence will further elevate the brand experience for connoisseurs throughout the region." This partnership marks a strategic step in AIMS’s global expansion, further solidifying its leadership in integrating high-end lifestyle offerings with advanced trading platforms. Moving forward, both parties will jointly explore greater cross-sector value, providing high-end clients with a new dimension of experience that combines luxurious taste with excellent performance. About AIMS AIMS is a brand with an 11-year industry heritage and a trusted financial broker for institutional and individual traders worldwide. With a global presence spanning more than 21 countries and regions, the broker is renowned for its high-performance trading platforms, highly competitive spreads, and client-centric service philosophy, continuously driving development and innovation in the global trading industry. For more information about Aims, please visit www.aimsfx.com or follow their social media accounts on Facebook, Instagram and Tiktok. Media Contact: Benson Low, AIMS Email: media@aimsfx.com Website: www.aimsfx.com
NAIROBI, Kenya and NEWPORT BEACH, Calif., Jan. 16, 2026 /PRNewswire/ -- The Open University of Kenya (OUK) and MindHYVE.ai, Inc., a U.S.-based artificial intelligence company, have signed a Memorandum of Understanding (MoU) establishing a strategic collaboration focused on advancing AI-powered learning enablement and academic innovation. A new chapter in digital education: MindHYVE.ai™ and The Open University of Kenya unite to pioneer AI-driven learning The collaboration explores the integration of ArthurAI™, MindHYVE.ai's proprietary agentic artificial intelligence system, into selected areas of OUK's digital learning ecosystem. The initiative is designed to support personalized learning, faculty enablement, data-driven curriculum innovation and workforce-aligned upskilling, positioning OUK as a leader in next-generation digital education across Africa. Under the MoU, the parties will jointly explore implementation of ArthurAI as a virtual academic enabler, supporting learners and educators through adaptive, real-time learning assistance. The collaboration also includes curriculum co-design, impact evaluation, localization aligned with Kenya's education policy and adherence to the Kenya Data Protection Act (2019). "This collaboration reflects the Open University of Kenya's commitment to innovation, access and academic excellence," said Professor Elijah Omwenga, Vice-Chancellor of the Open University of Kenya. "By exploring responsible AI-powered learning systems, we aim to enhance student success, empower faculty and strengthen Kenya's position as a digital education leader." "OUK represents a bold and forward-looking model for higher education in the digital age," said Bill Faruki, Founder and CEO at MindHYVE.ai™. "This collaboration allows us to responsibly explore how agentic AI can support learning, teaching and workforce readiness—while maintaining transparency, ethics and local relevance." This collaboration reflects a shared vision to advance responsible AI in education, expand access to high-quality digital learning and support Kenya's broader goals for workforce development and innovation. About The Open University of Kenya The Open University of Kenya (OUK), established by Charter in August 2023, is Kenya's first fully online specialised public University. OUK is mandated to expand access to affordable, flexible, self-paced, inclusive and high-quality higher education through digital and open learning innovation. It offers Professional Development Courses, Undergraduate and Postgraduate Programmes designed to meet the needs of learners across Kenya and beyond. Website: https://ouk.ac.ke/ ∕ Email: info@ouk.ac.ke ∕ Contact: +254 703 211 211 Media Contact:Brendah KabindioEmail: bkabindio@ouk.ac.ke About MindHYVE.ai™ MindHYVE.ai™ is redefining the boundaries of intelligence by engineering autonomous systems and deploying domain-specific AGI agents across real-world sectors. Powered by the Ava-Fusion™ large reasoning model and architected for agent coordination, swarm intelligence, and adaptive autonomy, MindHYVE's technology stack is revolutionizing law, medicine, finance, education, and governance. With operations in North America, Asia, and Africa, MindHYVE.ai™ is on a mission to democratize access to transformative intelligence and architect the infrastructure for post-scarcity economies. Backed by HYVE Labs, the company continues to shape the future of agentic systems on a global scale. Website: www.mindhyve.ai | Email: hello@mindhyve.io | Contact: +1 (949) 200-8668 Media Contact:Marc OrtizEmail: marc.ortiz@mindhyve.io
SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 (a CLDN18.2 antibody-drug conjugate [ADC]), as well as R&D progress on ATG-125 (a B7-H3 x PD-L1 bispecific ADC), its steric hindrance masking AnTenGager™ T cell engager (TCE) platform, and other key preclinical programs. 1. Core Clinical Program: ATG-022 Latest data from the Phase I/II CLINCH study: As of December 25, 2025, among patients with moderate to high CLDN18.2 expression (IHC 2+ > 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 40% (12/30) and the disease control rate (DCR) was 90% (27/30), with a median progression-free survival (mPFS) of 5.09 months and a median overall survival (mOS) of 14.72 months. In the 1.8 mg/kg dose cohort, the ORR was 46.7% (14/30), the DCR was 86.7% (26/30), the mPFS was 6.97 months, and the mOS has not yet been reached. Among patients with low/ultra-low CLDN18.2 expression (IHC 2+ ≤ 20%) treated at the efficacious dose range of 1.8-2.4 mg/kg, the ORR was 28.6% (6/21). In addition, one patient in each of the three dose groups achieved a complete response (CR). These results demonstrated the potent anti-tumor activity of ATG-022 across all levels of CLDN18.2 expression. Promising frontline combination potential: Compared with the data presented at the Company's R&D Day in November last year, the 1.8 mg/kg dose group demonstrated afurther improvement in ORR and a meaningful prolongation in mPFS, while maintaining a favorable safety profile. The incidence of Grade 3 or higher treatment-related adverse events (TRAEs) was only 19.4%. This differentiated safety profile positions ATG-022 as a potentially best-in-class ADC in terms of safety, with the potential to be combined with checkpoint inhibitors (CPIs) and chemotherapy to transform the current frontline standard-of-care regimen. First Disclosure of Positive Clinical Signals of ATG-022 in Non-Gastrointestinal Tumors: As of January 6, 2025, among 9 efficacy evaluable patients, the ORR was 22.2% (2/9), and DCR was 88.9% (8/9). These data suggest that ATG-022 may have the potential to treat CLDN18.2-positive non-gastrointestinal tumors, which could expand the treatable patient population beyond gastrointestinal cancers. The efficacy observed to date also supports further exploration of CLDN18.2 as a pan-tumor therapeutic target. Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and the Phase Ib/II CLINCH-2 study of ATG-022 in Mainland of China and Australia. The Company continues to advance the clinical development of ATG-022 across different lines of gastric cancer treatment, including first-line therapy in combination with checkpoint inhibitors (CPIs) and chemotherapy (CAPOX/FOLFOX); second-line therapy in combination with CPIs; and third-line therapy as monotherapy, covering patients with varying levels of CLDN18.2 expression. In addition, the CLINCH study of ATG-022 includes a basket trial cohort evaluating multiple tumor types, with the majority of patients continuing to receive treatment. 2. Next-Generation ADCs and Proprietary TCEs ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO+ADC " dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of immuno-oncology (IO) therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive signaling, ATG-125 effectively activates T cells and induces immunological memory. Preclinical studies demonstrate that the bispecific ADC delivers superior in vivo efficacy compared with single-target B7-H3-ADC or PD-L1-ADC approaches. The Company plans to submit an IND for ATG-125 in Q1 2027. TCE platform with steric hindrance masking technology: AnTenGager™ is Antengene's proprietary, second-generation T cell engager (TCE) platform featuring "2+1" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. Leveraging this platform, Antengene has discovered multiple investigational programs: ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel "2+1" CD19-targeted T-cell engager developed on the AnTenGager™ TCE platform for the treatment of B cell related autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology (ACR) Annual Meeting showed that in non-human primate (NHP) models, the monkey surrogate of ATG-201 achieved deep and durable depletion of naïve B cells with a favorable safety profile, characterized by only a very mild and transient increase in cytokine levels. The IND-enabling study of ATG-201 has been completed and the IND-submission is under preparation. ATG-106 (CDH6 x CD3 TCE): A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer. The Company plans to submit an IND for ATG-106 in the first half of 2027. ATG-112 (ALPPL2 x CD3 TCE): A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumor, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The Company has nominated a preclinical candidate (PCC) in January 2026. Additional TCE programs for solid tumors: Antengene plans to submit an IND for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer. In addition, ATG-115 (an undisclosed bispecific antibody) and two undisclosed trispecific antibody programs are currently in preclinical development. 3. Innovative Treatment for Autoimmune Diseases: Globally First-in-Class ATG-207 ATG-207 is a globally first-in-class dual-function biologic being developed for the treatment of T cell–mediated autoimmune diseases. The Company plans to present the preclinical data for ATG-207 for the first time at an international scientific conference in 2026. About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC) , ATG-037 (oral CD73 inhibitor) , ATG-101 (PD-L1 × 4-1BB bispecific antibody) , ATG-031 (CD24-targeting macrophage activator) , and ATG-042 (oral PRMT5-MTA inhibitor). Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies indications. To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor) , is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore). Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: donald.lung@antengene.com BD Contacts:Ariel GuoE-mail: ariel.guo@antengene.com
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
